利妥昔单抗治疗多发性硬化后严重中性粒细胞减少症。
Severe neutropenia after rituximab-treatment of multiple sclerosis.
机构信息
Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Turku, Finland.
Department of clinical haematology and stem cell transplantation, Turku University Hospital and University of Turku, Turku, Finland.
出版信息
Mult Scler Relat Disord. 2018 Feb;20:3-5. doi: 10.1016/j.msard.2017.12.005. Epub 2017 Dec 12.
We present here the first MS-case where rituximab-treatment led to grade IV neutropenia, with hospitalization and treatment of a serious infection with broad-spectrum antibiotics. The neutropenia resolved promptly with granulocyte-colony stimulating factor-treatment and the patient recovered well. Due to risk of recurring neutropenia rituximab-treatment was not re-administered. We discuss the mechanisms and occurrence of neutropenia as a side effect to rituximab-treatment of MS, and remind of the importance of monitoring rituximab-treated MS-patients for this rare but potentially dangerous side effect.
我们在此介绍首例多发性硬化症（MS）患者，其利妥昔单抗（rituximab）治疗后出现 IV 级中性粒细胞减少症，需住院并接受广谱抗生素治疗严重感染。中性粒细胞减少症经粒细胞集落刺激因子（granulocyte-colony stimulating factor）治疗后迅速缓解，患者恢复良好。由于存在中性粒细胞减少症复发的风险，未再次给予利妥昔单抗治疗。我们讨论了利妥昔单抗治疗 MS 导致中性粒细胞减少症的机制和发生情况，并提醒注意监测接受利妥昔单抗治疗的 MS 患者出现这种罕见但潜在危险的副作用的重要性。
Zotero 插件